Cargando…
Anti-Tumor Activity and Pharmacokinetics of AP25-Fc Fusion Protein
AP25 is an anti-tumor peptide with a high affinity for integrins. It exerts its anti-tumor activity by inhibiting angiogenesis and by directly inhibiting the growth of tumor cells. Its half-life time in vivo is only about 50 minutes, which limits its clinical application. In order to prolong the hal...
Autores principales: | Pei, Dening, Hu, Jialiang, Rao, Chunming, Yu, Pengcheng, Xu, Hanmei, Wang, Junzhi |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Ivyspring International Publisher
2019
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6643120/ https://www.ncbi.nlm.nih.gov/pubmed/31341417 http://dx.doi.org/10.7150/ijms.34365 |
Ejemplares similares
-
Optimized functional and structural design of dual-target LMRAP, a bifunctional fusion protein with a 25-amino-acid antitumor peptide and GnRH Fc fragment
por: Li, Meng, et al.
Publicado: (2020) -
Development and Validation of a Reporter-Cell-Line-Based Bioassay for Therapeutic Soluble gp130-Fc
por: Yu, Lei, et al.
Publicado: (2019) -
Pharmacokinetics of monoclonal antibodies and Fc-fusion proteins
por: Liu, Liming
Publicado: (2017) -
The Protective Effect of a Long-Acting and Multi-Target HM-3-Fc Fusion Protein in Rheumatoid Arthritis
por: Huang, Ruijing, et al.
Publicado: (2018) -
Pharmacokinetics and Pharmacodynamics of Recombinant Human EPO-Fc Fusion Protein In Vivo
por: Shi, Xunlong, et al.
Publicado: (2013)